Proton Pump Inhibitors in Gastroesophageal Reflux Disease: Friend or Foe

被引：20
作者：
Gyawali C.P. [1 ]
机构：
[1] Division of Gastroenterology, Washington University School of Medicine, 660 S. Euclid Ave, Campus Box 8124, St. Louis, 63110, MO
来源：
Current Gastroenterology Reports | 2017年 / 19卷 / 9期
关键词：
Ambulatory reflux monitoring; Endoscopy; Esophageal manometry; Gastroesophageal reflux disease; Proton pump inhibitors: heartburn;
D O I：
10.1007/s11894-017-0586-5
中图分类号：
学科分类号：
摘要：
Purpose of Review: Proton pump inhibitor (PPI) use in gastroesophageal reflux disease (GERD) has been redefined, in light of recent advances highlighting GERD phenotypes that respond to PPIs, and fresh revelations of potential risks of long-term PPI therapy. Recent Findings: Erosive esophagitis predicts excellent response to PPI therapy, but non-erosive reflux disease (NERD) with abnormal reflux parameters on ambulatory reflux monitoring also demonstrates a similar response. In contrast, response is suboptimal in the absence of abnormal reflux parameters. In this setting, if an alternate appropriate indication for PPI therapy does not coexist, risks may outweigh benefits of PPI therapy. Adverse events from long-term PPI therapy continue to be reported, most based on association rather than cause-and-effect. Summary: Appropriate indications need to be established before embarking on long-term PPI therapy. Future research will define true risks of long-term PPI therapy, and develop alternate management options for acid peptic diseases. © 2017, Springer Science+Business Media, LLC.
引用
收藏
相关论文
共 100 条
  • [1] Wolfe M.M., Sachs G., Acid suppression: optimizing therapy for gastroduodenal ulcer healing, gastroesophageal reflux disease, and stress-related erosive syndrome, Gastroenterology, 118, pp. S9-S31, (2000)
  • [2] Gralnek I.M., Dulai G.S., Fennerty M.B., Et al., Esomeprazole versus other proton pump inhibitors in erosive esophagitis: a meta-analysis of randomized clinical trials, Clin Gastroenterol Hepatol, 4, pp. 1452-1458, (2006)
  • [3] Fass R., Ofman J.J., Gralnek I.M., Et al., Clinical and economic assessment of the omeprazole test in patients with symptoms suggestive of gastroesophageal reflux disease, Arch Intern Med, 159, pp. 2161-2168, (1999)
  • [4] Fass R., Ofman J.J., Sampliner R.E., Et al., The omeprazole test is as sensitive as 24-h oesophageal pH monitoring in diagnosing gastro-oesophageal reflux disease in symptomatic patients with erosive oesophagitis, Aliment Pharmacol Ther, 14, pp. 389-396, (2000)
  • [5] Numans M.E., Lau J., de Wit N.J., Et al., Short-term treatment with proton-pump inhibitors as a test for gastroesophageal reflux disease: a meta-analysis of diagnostic test characteristics, Ann Intern Med, 140, pp. 518-527, (2004)
  • [6] Sheikh I., Waghray A., Waghray N., Et al., Consumer use of over-the-counter proton pump inhibitors in patients with gastroesophageal reflux disease, Am J Gastroenterol, 109, pp. 789-794, (2014)
  • [7] Lanas A., We are using too many PPIs, and we need to stop: a European perspective, Am J Gastroenterol, 111, pp. 1085-1086, (2016)
  • [8] Freedberg D.E., Kim L.S., Yang Y.X., The risks and benefits of long-term use of proton pump inhibitors: expert review and best practice advice from the American Gastroenterological Association, Gastroenterology, 152, pp. 706-715, (2017)
  • [9] Kahrilas P.J., Shaheen N.J., Vaezi M.F., Et al., American Gastroenterological Association Medical Position Statement on the management of gastroesophageal reflux disease, Gastroenterology, 135, (2008)
  • [10] Vela M.F., Camacho-Lobato L., Srinivasan R., Et al., Simultaneous intraesophageal impedance and pH measurement of acid and nonacid gastroesophageal reflux: effect of omeprazole, Gastroenterology, 120, pp. 1599-1606, (2001)
12345678910